COLLIS STEVEN H

Director Collis Steven H buys 3,000 shares of ELV at $289.84, tripling holdings to 3,639 shares (+469.5%)

Director Collis Steven H purchased 3,000 shares of Elevance Health for $869,520.00 on 2026-03-05, increasing his holdings from 639 to 3,639 shares—a 469.5% increase from his prior position. The purchase occurred at $289.84 per share, while the stock trades at $289.64 today, approximately 36.0% below its 52-week high of $452.69 and down 15.0% over the past 30 days. The company trades at a 12.26 P/E with solid fundamentals ($50.7B quarterly revenue, $1.2B net income, 12.5% annual growth). Notably, across his cross-ticker open-market history, this director has completed only 1 prior buy against 19 prior sells; his sell-timing record shows a 26.32% well-timed rate and 5.9% average 90-day return, indicating his historical sales have generally been followed by further declines. This buy represents a material shift in activity pattern and a substantial increase in personal position concentration.

Director Collis Steven H buys 15,000 shares of BLCO at $17.81; holdings increase 153.9%. 2 other insiders also bought in past 14 days.

Director Collis Steven H purchased 15,000 shares at $17.81 on 2026-02-23, raising his holdings from 9,746 to 24,746 shares—a 153.9% increase in position size. The stock is at $18.44, near its 52-week high of $18.44, after gaining +13.8% over the past 90 days. Alongside this buy, 2 other insiders purchased shares within the past 14 days, forming a cluster acquisition pattern. BLCO is unprofitable (latest quarter net income: $-28.0M), though revenue grew +6.5% year-over-year to $1,281,000,000.00. The coincident buying by multiple insiders during near-peak valuations—coupled with the company's current unprofitability—warrants observation of whether this reflects conviction in a recovery path or responds to other considerations.

Executive Chairman Collis sold 31,350 shares of COR at $289.86 for $9.1M, reducing stake by 9.3%.

Steven H. Collis, Executive Chairman, executed a discretionary sale of 31,350 shares on 2025-09-16 at $289.86 per share, totaling $9,087,142.35. The sale reduced his holdings from 337,262 shares to 305,912 shares, representing a 9.3% reduction in his position. His cross-ticker track record across 20 prior open-market sales shows an average 90-day return of +4.0%, with a 90-day well-timed rate of 29.41%, suggesting modest historical accuracy in timing. At COR specifically, his prior five trades show mixed outcomes—two of the measurable 90-day periods were negative (the 2025-05-20 and 2025-06-24 sales underperformed), while his oldest measurable trade (2025-04-22) returned +3.8% over 90 days. The current stock price of $290.84 is 4.5% below the 52-week high of $304.58, and the company carries a P/E of 29.71 on $80.7B in annual revenue with 12.1% year-over-year growth. This sale occurs within the context of a strong fundamental position but does not alone indicate a change in conviction about the company's trajectory.

Executive Chairman Collis Steven H sells 14,579 shares of COR at $289.98 for $4.2M; stock up 3.8% in 30 days.

Collis Steven H, Executive Chairman of Cencora, Inc., sold 14,579 shares at $289.98 on 2025-08-19, reducing his holdings by 4.5% to 307.9K shares post-transaction. COR has appreciated 3.8% over the prior 30 days and trades within 0.3% of its 52-week high, suggesting a sale near a recent peak. His cross-ticker track record shows 20 prior open-market sales with an average 90-day well-timed rate of 27.78%, but his same-ticker history at COR is mixed: only 1 of 3 measurable prior sells at COR was well-timed at the 90-day mark, with the most recent prior sale on 2025-07-22 too recent for outcome measurement. The company's fundamentals remain robust (Revenue $80.7B, annual growth +12.1%, P/E 31.02), so the sale does not suggest material operational deterioration, though the frequency of sales in recent months (5 in the last 4 months) warrants observation of transaction timing patterns.

Executive Chairman Steven Collis sold 14,578 COR shares at $292.67 for $4.3M, reducing stake to 309.9K shares

Steven Collis, Executive Chairman of Cencora, sold 14,578 shares at $292.67 on 2025-07-22, reducing his post-transaction holdings to 309.9K shares (a -4.5% reduction). This is his sixth open-market sale of COR stock in roughly four months; his prior five trades at this ticker show positive 30-day and 90-day returns (ranging +1.0% to +4.8% at 30 days, and +3.8% to +8.8% at 90 days), meaning the stock rose after those sales rather than fell. His cross-ticker track record shows an average 90-day return of +5.8% after sells, with a well-timed rate of 22.22% (sells are well-timed when the stock falls afterward). At the $293.44 current price, the stock is -3.7% from its 52-week high and has risen +3.9% over 90 days. The underlying business shows solid fundamentals: $75.5B in latest-quarter revenue, +12.1% annual growth, and $717.9M in net income, though the P/E of 33.57 reflects elevated valuation.

Executive Chairman Collis Steven H sold 14,579 shares of COR for $4.3M; stock now -4.0% from 52-week high. Routine stake reduction.

Collis Steven H, Executive Chairman of Cencora, Inc., sold 14,579 shares on 2025-06-24 at $292.62 per share, reducing his holdings by 4.5% to 311.9K shares. The timing aligns with stock strength near 52-week highs ($304.58), though current price at $292.32 sits -4.0% below that peak. His prior trades at COR show mixed outcomes: three measurable sales (Feb-27, Mar-25 x2) each generated positive 90-day returns of +9.6%, +4.8%, and +4.8% respectively, indicating the stock rose after those sales rather than declined. This cross-ticker track record also reflects a low 90d well-timed rate of 22.22%, suggesting his sell timing historically has not been sharply predictive of imminent price declines. The sale occurs at a valuation of P/E 33.45 with the company posting +12.1% annual revenue growth and $56.7B market cap—macro conditions appear stable rather than distressed.

Executive Chairman COLLIS STEVEN H sells 14,578 shares of COR at $293.84; holds 313,912 post-transaction

COLLIS STEVEN H sold 14,578 shares at $293.84, reducing his stake by 4.4% to 313,912 shares held post-transaction. The sale occurred near the 52-week high of $304.58 (within -4.3%), and the stock has rallied +3.6% over 30 days and +19.7% over 90 days. His cross-ticker track record shows 20 prior sells with a 90d well-timed rate of 26.67%, while his same-ticker history at COR shows 5 prior trades, all sells, with measurable 30-day returns ranging from +4.8% to +9.6%—indicating recent sells have been followed by further gains. The timing of this sale relative to price strength warrants observation given the stock's elevated valuation (P/E 33.34) and the mixed signal between the strong recent momentum and his historical sell pattern.

Executive Chairman Collis sold 14,579 shares of COR at $281.81 on 2025-04-22 ($4.1M); retains 315.9K shares.

Collis Steven H executed a sale of 14,579 shares (14.6K shares) at $281.81, representing a -4.4% reduction in his holdings to 315.9K shares. The sale occurred at a price just 1.6% below the 52-week high of $289.36, during a period of strong momentum (stock up 6.4% over 30 days and 14.8% over 90 days). His cross-ticker track record shows a 31.25% well-timed rate on prior sells with a 90-day average return of +4.8%, but his five prior trades at COR include two incomplete measurable outcomes, one well-timed sell in November 2024 (-1.0% 90-day return), and two February trades showing positive 30-day returns of +9.6%. With COR trading at a P/E of 39.54 and posting strong fundamentals ($81.5B revenue, +12.1% YoY growth), the timing relative to recent price strength and the modest size of this reduction (from substantial holdings) provide limited directional insight into conviction changes.

Cencora Executive Chairman Steven Collis sells 14,578 shares for $3,928,916.78 at $269.51.

Steven Collis executed 2 separate sales totaling 14,578 shares for $3,928,916.78 on 2025-03-25, reducing his holdings by 4.4% to 317,912 shares. The sale occurred near the 52-week high (current price $271.39 is +0.0% from the 52-week high), though this represents a single transaction rather than a pattern. His prior COR sales have produced mixed outcomes: one well-timed 90-day decline and two sales that posted positive 90-day returns, yielding a 1-of-3 well-timed rate at this ticker. His cross-ticker track record shows a 33.33% well-timed rate on 20 prior sells with an average 90-day return of +4.0%, suggesting his sales historically have not preceded material declines. The company's fundamentals remain solid with $81.5B in revenue, +12.1% annual growth, and a P/E of 37.69.

Collis (Exec Chairman) sold 14,579 shares for $3,660,495.32 at Cencora; stock trading near 52-week highs.

Cencora's Executive Chairman Steven Collis executed 2 separate sales on 2025-02-27, totaling 14,579 shares for $3,660,495.32 at a blended price of $251.08, reducing his holdings from 334,491 shares to 319,912 shares. At $253.54 current price, the stock is trading at -1.9% from its 52-week high of $258.46, within its established range. Collis's cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 30.00%, while at COR specifically he has achieved well-timing on 2 of 5 prior sells at the 90-day mark—a mixed pattern. The company fundamentals are solid: $81.5B in quarterly revenue, +12.1% annual growth, and a P/E of 35.21, though the valuation remains elevated relative to broader market multiples.